Licensing Packaging Protein RNA 
The Pharma Data
DECEMBER 8, 2020
The company’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. Laying down a new track for RNA processing, Remix launched with $81 million in financing.
Pfizer
AUGUST 15, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. FDA Emergency Use Authorization Statement. anti-infectives).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
JANUARY 27, 2023
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus.
pharmaphorum
DECEMBER 13, 2021
It, too, announced plans to invest $500 million in a new facility in Africa for the production, fill/finish and packaging of mRNA vaccines. Dormitzer comes from Pfizer, where he was chief scientific officer for RNA and viral vaccines for more than six years. But Sanofi, didn’t stop there. It may have sold its 7.7%
Pfizer
DECEMBER 13, 2021
The teams started changing existing filling lines, building formulations booths and new filling lines, constructing packaging lines and a “freezer farm,” while recruiting and training new colleagues. 1 They collaborated on methods to purify the RNA using a process called tangential flow filtration, which removes unneeded materials.
Pfizer
DECEMBER 13, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. For more information, please visit www.PAXLOVID.com. .
Pfizer
DECEMBER 20, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. For more information, please visit www.PAXLOVID.com.
Expert insights. Personalized for you.
52 
Let's personalize your content